CTRI/2023/12/060529进行中（未招募）2 期
An investigator-initiated phase II randomized controlled trial of low-dose pembrolizumab in addition to standard neoadjuvant chemotherapy in patients with triple negative breast cancer - NI
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients who are diagnosed with triple negative breast cancer.
- •2. Patients who are planned to give NACT.
排除标准
- •1. Patients who are not TNBC.
- •2. Patients who are not given NACT.
研究者
相似试验
进行中（未招募）
2 期
A phase II investigator-initiated randomized, double blind, parallel-group clinical trialof 5-aminolevulinic acid hydrochloride/ sodium ferrous citrate (5-ALA-HCl/ SFC) for patients with adult-onset still's disease (AOSD) refractory to corticosteroidsJPRN-jRCT2071220040Kawakami Atsushi30
进行中（未招募）
1 期
Study evaluating weekly oral vinorelbine versus weekly paclitaxel in a population of patients with advanced breast cancer.advanced breast cancer with estrogen receptor positive and HER2 negative.MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2012-003530-16-FRPIERRE FABRE MEDICAMENT124
进行中（未招募）
1 期
Study evaluating weekly oral vinorelbine versus weekly paclitaxel in a population of patients with advanced breast cancer.EUCTR2012-003530-16-ESPIERRE FABRE MEDICAMENT124
进行中（未招募）
不适用
Study evaluating weekly oral vinorelbine versus weekly paclitaxel in a population of patients with advanced breast cancer.advanced breast cancer with estrogen receptor positive and HER2 negative.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2012-003530-16-ATPIERRE FABRE MEDICAMENT124
进行中（未招募）
1 期
Study evaluating weekly oral vinorelbine versus weekly paclitaxel in a population of patients with advanced breast cancer.EUCTR2012-003530-16-PLPIERRE FABRE MEDICAMENT124